Pulegone and Eugenol Oral Supplementation in Laboratory Animals: Results from Acute and Chronic Studies

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Carla M. Ribeiro Silva (Author) Other; Ana I. Faustino Rocha (Author) Other; Rui M. Gil da Costa (Author) Other; Rui Medeiros (Author) Other; Maria J. Pires (Author) Other; Isabel Gaivão (Author) Other; Adelina Gama (Author) Other; Maria J. Neuparth (Author) Other; Joana V. Barbosa (Author) FEUP; Francisco Peixoto (Author) Other; Fernão D. Magalhães (Author) Other; Margarida M. S. M. Bastos (Author) FEUP; Paula A. Oliveira (Author) Other

Journal

Title: Biomedicines

Vol. 10

Pages: 1-2595

Publisher: MDPI

Indexing

ISI Web of Knowledge - 8 Citations

Scopus

Associated Projects

ALiCE - ALiCE - Laboratório Associado em Engenharia Química

LEPABE - Financiamento Plurianual 2020-2023 da Unidade de I&D LEPABE - Laboratório de Engenharia de Processos, Ambiente, Biotecnologia e Energia

2SMART - 2SMART - engineered Smart materials for Smart citizens

Other information

Authenticus ID: P-00X-BEA

DOI: 10.3390/biomedicines10102595

Abstract (EN): Essential oils are natural compounds used by humans for scientific purposes due to their wide range of properties. Eugenol is mostly present in clove oil, while pulegone is the main constituent of pennyroyal oil. To guarantee the safe use of eugenol and pulegone for both humans and animals, this study addressed, for the first time, the effects of these compounds, at low doses (chronic toxicity) and high doses (acute toxicity), in laboratory animals. Thirty-five FVB/n female mice were randomly assigned to seven groups (n = 5): group I (control, non-additive diet); group II (2.6 mg of eugenol + 2.6 mg of pulegone); group III (5.2 mg of eugenol + 5.2 mg of pulegone); group IV (7.8 mg of eugenol + 7.8 mg of pulegone); group V (7.8 mg of eugenol); group VI (7.8 mg of pulegone); and group VII (1000 mg of eugenol + 1000 mg of pulegone). The compounds were administered in the food. Groups I to VI were integrated into the chronic toxicity study, lasting 28 days, and group VII was used in the acute toxicity study, lasting 7 days. Animals were monitored to assess their general welfare. Water and food intake, as well as body weight, were recorded. On the 29th day, all animals were euthanized by an overdose of ketamine and xylazine, and a complete necropsy was performed. Blood samples were collected directly from the heart for microhematocrit and serum analysis, as well as for comet assay. Organs were collected, weighed, and fixed in formaldehyde for further histological analysis and enzymatic assay. Eugenol and pulegone induced behavioral changes in the animals, namely in the posture, hair appearance and grooming, and in mental status. These compounds also caused a decrease in the animals' body weight, as well as in the food and water consumption. A mortality rate of 20% was registered in the acute toxicity group. Both compounds modulated the serum levels of triglycerides and alanine aminotransferase. Eugenol and pulegone induced genetic damage in all animals. Eugenol increased the activity of the CAT enzyme. Both compounds increased the GR enzyme at the highest dose. Moreover, pulegone administered as a single compound increased the activity of the GST enzyme. Histopathological analysis revealed inflammatory infiltrates in the lungs of groups II, III, and IV. The results suggest that eugenol and pulegone may exert beneficial or harmful effects, depending on the dose, and if applied alone or in combination.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 21